Late Metastases from a Thin Primary Cutaneous Malignant Melanoma
Abstract
Cutaneous malignant melanoma is the third most common type of skin cancer, and its incidence has been rising. Its mortality rate is considerable, due to an aggressive phenotype and great ability of dissemination, mainly in the first years of follow- -up. Late recurrences, those presenting more than 10 years after diagnosis, are rare. The main prognostic factor of cutaneous malignant melanoma is tumor thickness, which also guides management. Thin tumors often have a good prognosis. We report a case of a 66-year-old woman with a history of excision of a thin primary cutaneous malignant melanoma of the dorsum, presenting 16 years later with an unexpected, rapidly progressing and lethal recurrence.
Downloads
References
Whiteman DC, Green AC, Olsen CM. The Growing Burden of Invasive Melanoma: Projections of Incidence Rates and Numbers of New Cases in Six Susceptible Populations through 2031. J Invest Dermatol. 2016;136:1161-71. doi: 10.1016/j.jid.2016.01.035.
Vukomanovic P, Karanikolic A, Stefanoviic M, Mihajlovic D, Djordjevic B, Kutlesic R. Late recurrence of malignant melanoma mimicking ovarian malignancy. Eur J Gynaecol Oncol. 2010;31:590-2.
Mansour D, Kejariwal D. It is never too late: ultra-late recurrence of melanoma with distant metastases. BMJ Case Rep. 2012:bcr0120125474. doi: 10.1136/bcr.01.2012.5474.
Ruiz-Cuesta P, Hervás-Molina AJ, Villar-Pastor CM, Jurado-García J, Barrera-Baena P. Metastasis gastrica tardia de melanoma cutaneo. Gastroenterol Hepatol. 2014;37:564-5. doi: 10.1016/j.gastrohep.2014.01.009.
Osella-Abate S, Ribero S, Sanlorenzo M, Maule MM, Richiardi L, Merletti F, et al. Risk factors related to late metastases in 1,372 melanoma patients disease free more than 10 years. Int J Cancer. 2015;136:2453-7. doi: 10.1002/ijc.29281
Hansel G, Schönlebe J, Haroske G, Wollina U. Late recurrence (10 years or more) of malignant melanoma in south-east Germany (Saxony). A single-centre analysis of 1881 patients with a follow-up of 10 years or more. J Eur Acad Dermatol Venereol. 2010;24:833-6.
Damsky WE, Theodosakis N, Bosenberg M. Melanoma metastasis: new concepts and evolving paradigms. Oncogene. 2014;33:2413-22. doi: 10.1038/onc.2013.194.
Faries MB, Steen S, Ye X, Sim M, Morton DL. Late recurrence in melanoma: clinical implications of lost dormancy. J Am Coll Surg. 2013;217:27-34. doi: 10.1016/j.jamcollsurg.2013.03.007.
Swetter SM, Tsao H, Bichakjian CK, Curiel-Lewandrowski C, Elder DE, Gershenwald JE, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80:208-50. doi: 10.1016/j.jaad.2018.08.055.
Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Bastholt L, et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019. Eur J Cancer. 2020;126:141–58. doi: 10.1016/j.ejca.2019.11.014.
Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-48.
Brochez L, Verhaeghe E, Sales F, del Marmol V, Deraemaecker R, Vossaert K, et al. Current guidelines in melanoma treatment. Melanoma Working Group of Gent and Bordet. Dermatology. 2000;200:160-6.
Dunn CL, Zitelli JA. Standards of care for patients with malignant melanoma. J Am Acad Dermatol. 2000;43:155-8.
Kanzler MH, Mraz-Gernhard S. Primary cutaneous malignant melanoma and its precursor lesions: diagnostic and therapeutic overview. J Am Acad Dermatol. 2001;45:260-76.
Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Bastholt L, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019. Eur J Cancer. 2020;126:159–77. doi: 10.1016/j.ejca.2019.11.015.
Kyrgidis A, Tzellos T, Mocellin S, Apalla Z, Lallas A, Pilati P, et al. Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma. Cochrane Database Syst Rev. 2015;5:CD010307. doi:10.1002/14651858.CD010307.pub2.
Stiegel E, Xiong D, Ya J, Funchain P, Isakov R, Gastman B, et al. Prognostic value of sentinel lymph node biopsy according to Breslow thickness for cutaneous melanoma. J Am Acad Dermatol. 2018;78:942-8. doi: 10.1016/j.jaad.2018.01.030.
Gimotty PA, Guerry D, Ming ME, Elenitsas R, Xu X, Czerniecki B, et al. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol. 2004;22:3668-76.
Tsao H, Cosimi AB, Sober AJ. Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer. 1997;79:2361-70.
Pizzichetta MA, Talamini R, Stanganelli I, Puddu P, Bono R, Argenziano G, et al. Amelanotic/hypomelanotic melanoma: clinical and dermoscopic features. Br J Dermatol. 2004;150:1117-24.
All articles in this journal are Open Access under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
